SEL-212 clinical trials
Also written SEL-212.
How each study uses SEL-212 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Selecta Biosciences, Inc. (3) · Swedish Orphan Biovitrum (2)
Often tested with
Tested in the same studies.
Pegadricase (2) · Synthetic Vaccine Particles-Rapamycin (1)
Studies
Open first, then newest update. How each study uses SEL-212 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy IICompletedPhase 3Swedish Orphan BiovitrumNCT04596540Written as SEL-212 low-doseHow we know
- A Study of SEL-212 in Patients With Gout Refractory to Conventional TherapyCompletedPhase 3Swedish Orphan BiovitrumNCT04513366Written as SEL-212 low-doseHow we know
- A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional TherapyCompletedPhase 2Selecta Biosciences, Inc.NCT03905512Written as SEL-212How we know
- Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric AcidCompletedPhase 2Selecta Biosciences, Inc.NCT02959918Written as SEL-212How we know
- Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid LevelsCompletedPhase 1Selecta Biosciences, Inc.NCT02648269Written as SEL-212How we know